InsidersTradesSigma
Total declarations
Company
▲ Purchases (24 ops.)
▼ Sales (0 ops.)
Insider track record
CFODisclosed buys
24
Disclosed sells
0
T+90 hit rate
11%
T+90 mean return
-17.1%
Across 9 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Browse the detailed record of transactions filed by Byam Rebecca, Chief Financial Officer. Director active across 1 company, notably HCW Biologics Inc.. Cumulatively, 29 disclosures have been logged. Split: 24 buys · 0 sell. Total volume traded: €1.2m. History available since 22 July 2021. The latest transaction was filed on 22 May 2026 (Acquisition). Regulator: SEC (Form 4). The full history is openly available.
Declarations29 total
14,235 shares@ US$1.4050.21% mcap0.8% of flowCommon StockSEC:0001493152-26-025474:0
Ideal exit: 16 Feb 2027 (T+270)
8,462 shares@ US$26.008.8% of flowCommon StockSEC:0000950170-25-068281:0
Ideal exit: 2 Feb 2026 (T+270)
760,714 shares@ US$1.4044.5% of flowCommon StockSEC:0001209191-24-003782:0
47,249 shares@ US$0.140.3% of flowCommon StockSEC:0001209191-23-053344:0
5,000 shares@ US$2.0980.4% of flowCommon StockSEC:0001209191-23-049650:0
Ideal exit: 9 Jun 2024 (T+270)
5,000 shares@ US$2.05460.4% of flowCommon StockSEC:0001209191-23-049314:0
Ideal exit: 7 Jun 2024 (T+270)
5,000 shares@ US$1.94840.4% of flowCommon StockSEC:0001209191-23-048824:0
Ideal exit: 3 Jun 2024 (T+270)
5,000 shares@ US$1.94980.4% of flowCommon StockSEC:0001209191-23-048651:0
Ideal exit: 2 Jun 2024 (T+270)
20,000 shares@ US$2.06431.7% of flowCommon StockSEC:0001209191-23-036040:0
Ideal exit: 5 Mar 2024 (T+270)
20,000 shares@ US$2.03161.7% of flowCommon StockSEC:0001209191-23-035581:0
Ideal exit: 3 Mar 2024 (T+270)
20,000 shares@ US$1.66721.4% of flowCommon StockSEC:0001209191-23-035121:0
Ideal exit: 1 Mar 2024 (T+270)
20,000 shares@ US$1.61741.4% of flowCommon StockSEC:0001209191-23-033173:0
Ideal exit: 19 Feb 2024 (T+270)
33,450 shares@ US$1.5262.1% of flowCommon StockSEC:0001209191-23-031923:0
Ideal exit: 16 Feb 2024 (T+270)
33,750 shares@ US$0.140.2% of flowCommon StockSEC:0001209191-22-055548:0
15,000 shares@ US$2.57671.7% of flowCommon StockSEC:0001209191-22-050074:0
Ideal exit: 11 Jun 2023 (T+270)
15,000 shares@ US$2.65091.8% of flowCommon StockSEC:0001209191-22-049866:0
Ideal exit: 9 Jun 2023 (T+270)
7,200 shares@ US$2.54740.8% of flowCommon StockSEC:0001209191-22-048239:0
Ideal exit: 27 May 2023 (T+270)
10,000 shares@ US$2.53581.1% of flowCommon StockSEC:0001209191-22-048016:0
Ideal exit: 23 May 2023 (T+270)
10,000 shares@ US$2.56621.2% of flowCommon StockSEC:0001209191-22-048016:1
Ideal exit: 26 May 2023 (T+270)
50,000 shares@ US$2.50455.7% of flowCommon StockSEC:0001209191-22-047721:0
Ideal exit: 21 May 2023 (T+270)
7,596 shares@ US$2.08170.18% mcap3.0% of flowCommon StockSEC:0001209191-22-037110:0
Ideal exit: 10 Mar 2023 (T+270)
27,000 shares@ US$0.140.2% of flowCommon StockSEC:0001209191-21-066900
27,000 shares@ US$0.140.041% mcap0.7% of flowCommon StockSEC:0001209191-21-066900:0
10,000 shares@ US$4.39790.46% mcap7.4% of flowCommon StockSEC:0001209191-21-055532:0
Ideal exit: 16 May 2022 (T+270)
10,000 shares@ US$4.39791.7% of flowCommon StockSEC:0001209191-21-055532
Ideal exit: 16 May 2022 (T+270)
25 of 29 declarations
About Byam Rebecca
Rebecca Byam is the Chief Financial Officer at HCW Biologics Inc. She is responsible for the company's financial management, including financial planning and performance analysis. Her expertise is essential to support the company's growth and profitability.
